NCCN VERSION 2 2015
NCCN Guidelines Version 2.2015 Invasive Breast Cancer
NCCN Guidelines Index Breast Cancer Table of Contents Discussion
HISTOLOGY
HORMONE RECEPTOR STATUS
HER2 STATUS
SYSTEMIC ADJUVANT TREATMENT
See Systemic Adjuvant Treatment - Hormone Receptor Positive - HER2-Positive Disease (BINV-5)
HER2-positive b
ER positive and/or PR positive
See Systemic Adjuvant Treatment - Hormone Receptor Positive - HER2-Negative Disease (BINV-6)
HER2-negative b
• Ductal u • Lobular • Mixed • Metaplastic
See Systemic Adjuvant Treatment - Hormone Receptor Negative - HER2-Positive Disease (BINV-7)
HER2-positive b
ER negative and PR negative
See Systemic Adjuvant Treatment - Hormone Receptor Negative - HER2-Negative Disease (BINV-8)
HER2-negative b
ER positive and/or PR positive
• Tubular • Mucinous
See Systemic Adjuvant Treatment - Favorable Histologies (BINV-9)
ER negative and PR negative
b See Principles of HER2 Testing (BINV-A) . u This includes medullary and micropapillary subtypes.
Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
BINV-4
Version2.2015, 03/11/2015© National Comprehensive Cancer Network, Inc. 2015,All rights reserved.The NCCN Guidelines ® and this illustration may not be reproduced in any form without the express written permission of NCCN ® .
Made with FlippingBook